Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 6/20 | 0.35 |
| ▸ | NOS3 | P29474 | 5/20 | 0.35 |
| ▸ | NOS1 | P29475 | 4/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12359188 | 0.75 | HTT (0.39) | NOS2NOS3GPR84TLR8CRHR1 | |
| SCHEMBL19480161 | 0.73 | NOS3 (0.36) | NOS2NOS3NOS1CRHR1 | |
| SCHEMBL4547885 | 0.72 | NOS2 (0.61) | NOS2NOS3NOS1KDM4EMEN1 | |
| SCHEMBL12250769 | 0.71 | NOS3 (0.41) | NOS2NOS3NOS1CRHR1 | |
| SCHEMBL26744077 | 0.71 | ADRB2 (0.34) | NOS2GPR84 | |
| SCHEMBL21711086 | 0.70 | MAPT (0.33) | KDM4E | |
| SCHEMBL19852985 | 0.70 | HTT (0.38) | NOS2NOS3GPR84TLR8MEN1 | |
| SCHEMBL19261307 | 0.69 | KCNH2 (0.41) | NOS2NOS3GPR84TLR8KDM4E | |
| SCHEMBL29316557 | 0.69 | KCNH2 (0.41) | NOS2NOS3GPR84TLR8KDM4E | |
| SCHEMBL11699835 | 0.69 | NOS2 (0.43) | NOS2NOS3NOS1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3041841-B1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2019-06-05 | — | — | EP | disclosed |
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | NOS2 1102/4885NOS3 1257/4885NOS1 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.